Free Trial Information
BioCentury | Nov 14, 2017
Regulation

Rules of engagement

An upcoming publication from the National Health Council on good practices for sponsor-patient interactions could help companies overcome fears that their outreach could be construed as promotional. Several executives told BioCentury that having guardrails established...
Read More
BioCentury | Apr 30, 2015
Top Story

Second draft of 21st Century Cures released

The U.S. House Energy & Commerce Committee released on Wednesday a slimmed-down (see BioCentury, March 15) . The draft includes new proposals, including a requirement that FDA evaluate the use of "clinical experience" rather than randomized...
Read More
BioCentury | Apr 15, 2013
Company News

ProScript management update

ProScript Inc., Cambridge, Mass. Business: Autoimmune/Inflammation Hired: Marlene Booth, as VP of project management, quality assurance and regulatory affairs; formerly senior director of regulatory affairs at Biopure Corp. Hired: Stacey Channing, as VP, patent and...
Read More
BioCentury | Jul 9, 2012
Strategy

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
Read More
BioCentury | Feb 4, 2008
Product Development

Velcade's true believers

...response. Consequently, MyoGenics switched its focus from cachexia to inflammation and changed its name to ProScript Inc....
...proteasome and actually have a higher turnover rate of proteins in the cell." In 1995, ProScript...
...was to develop PS-341 , as bortezomib was then called, for rheumatoid arthritis (RA), while ProScript...
Read More
BioCentury | Feb 4, 2008
Product Development

Velcade's history

...MyoGenics changes name to ProScript; focuses on inflammation 1995 Hoechst Marion Roussel signs deal with ProScript...
...Cancer Institute screens bortezomib against 60 cancer cell lines 1997 Hoechst returns rights Jul 1998 ProScript...
...each at MD Anderson, Sloan Kettering and University of North Carolina Jun 1999 LeukoSite acquires ProScript...
Read More
BioCentury | Sep 4, 2006
Strategy

Back to School 2006: Value for money

Thirteen years ago BioCentury sketched a picture called "The Clear Route to ROI" to depict the gap between the perceptions of value creation held by biotechnology companies and those of investors. Today a more mature...
Read More
BioCentury | Sep 5, 2005
Strategy

Back to School 2005: Innovation & economics

Entering the second half of the decade, and a five full years after the genomics bubble popped, the biopharmaceutical industry and its financiers are beset with doubts about business models, the ability to raise money,...
Read More
BioCentury | May 30, 2005
Finance

VPOs into the breach

...treat prostate cancer in the mid-1990s. At the time, bortezomib was in the hands of ProScript Inc....
...Mass.), which provided the compound to M.D. Anderson. "The Prostate Cancer Foundation came in when ProScript...
...and a contentious board," said Julian Adams, who was executive vice president of R&D at ProScript...
Read More
BioCentury | Dec 9, 2002
Finance

Tracking Millennium's departures

...pharmacology and drug development Joined MLNM in 1999 via LeukoSite acquisition; Elliot originally came from ProScript...
Read More
Items per page:
1 - 10 of 33
BioCentury | Nov 14, 2017
Regulation

Rules of engagement

An upcoming publication from the National Health Council on good practices for sponsor-patient interactions could help companies overcome fears that their outreach could be construed as promotional. Several executives told BioCentury that having guardrails established...
Read More
BioCentury | Apr 30, 2015
Top Story

Second draft of 21st Century Cures released

The U.S. House Energy & Commerce Committee released on Wednesday a slimmed-down (see BioCentury, March 15) . The draft includes new proposals, including a requirement that FDA evaluate the use of "clinical experience" rather than randomized...
Read More
BioCentury | Apr 15, 2013
Company News

ProScript management update

ProScript Inc., Cambridge, Mass. Business: Autoimmune/Inflammation Hired: Marlene Booth, as VP of project management, quality assurance and regulatory affairs; formerly senior director of regulatory affairs at Biopure Corp. Hired: Stacey Channing, as VP, patent and...
Read More
BioCentury | Jul 9, 2012
Strategy

Belviq breaks through

Arena Pharmaceuticals Inc. and partner Eisai Pharmaceuticals Co. Ltd. will have a fine line to walk as they market Belviq lorcaserin for obesity. They want to improve patient compliance, which historically has not been good...
Read More
BioCentury | Feb 4, 2008
Product Development

Velcade's true believers

...response. Consequently, MyoGenics switched its focus from cachexia to inflammation and changed its name to ProScript Inc....
...proteasome and actually have a higher turnover rate of proteins in the cell." In 1995, ProScript...
...was to develop PS-341 , as bortezomib was then called, for rheumatoid arthritis (RA), while ProScript...
Read More
BioCentury | Feb 4, 2008
Product Development

Velcade's history

...MyoGenics changes name to ProScript; focuses on inflammation 1995 Hoechst Marion Roussel signs deal with ProScript...
...Cancer Institute screens bortezomib against 60 cancer cell lines 1997 Hoechst returns rights Jul 1998 ProScript...
...each at MD Anderson, Sloan Kettering and University of North Carolina Jun 1999 LeukoSite acquires ProScript...
Read More
BioCentury | Sep 4, 2006
Strategy

Back to School 2006: Value for money

Thirteen years ago BioCentury sketched a picture called "The Clear Route to ROI" to depict the gap between the perceptions of value creation held by biotechnology companies and those of investors. Today a more mature...
Read More
BioCentury | Sep 5, 2005
Strategy

Back to School 2005: Innovation & economics

Entering the second half of the decade, and a five full years after the genomics bubble popped, the biopharmaceutical industry and its financiers are beset with doubts about business models, the ability to raise money,...
Read More
BioCentury | May 30, 2005
Finance

VPOs into the breach

...treat prostate cancer in the mid-1990s. At the time, bortezomib was in the hands of ProScript Inc....
...Mass.), which provided the compound to M.D. Anderson. "The Prostate Cancer Foundation came in when ProScript...
...and a contentious board," said Julian Adams, who was executive vice president of R&D at ProScript...
Read More
BioCentury | Dec 9, 2002
Finance

Tracking Millennium's departures

...pharmacology and drug development Joined MLNM in 1999 via LeukoSite acquisition; Elliot originally came from ProScript...
Read More
Items per page:
1 - 10 of 33